Cell & Gene: The Podcast

We love to hear from our listeners. Send us a message.During this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Jacques provides an update on FDA approval and details what’s next for RVT-802. She explains tissue-based therapies — how far they’ve come and the work that’s left to be done. And, they discuss what being patient-focused means in the world of rare diseases. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

We love to hear from our listeners. Send us a message.Cell & Gene, the online resource that delivers in-depth content from authoritative authors and sources to professionals in the CGT sector, is thrilled to introduce “Cell & Gene: The Podcast.” Cell and gene therapies offer huge potential to treat a wide range of diseases and their possibilities represent a new era in medicine. “Cell & Gene: The Podcast” will explore approved and pipeline therapies, new trends in manufacturing, the long, regulated road to commercialization, and everything in between. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to an industry or academic leader about their current initiatives and how they are moving the sector forward.  (Music by Royalty Free Music From Bensound) Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn